Navigation Links
bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
Date:12/10/2010

SAN DIEGO, Dec. 10, 2010 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

The company also announced that the Breast Cancer Index is now available to provide quantitative assessment of the risk of distant disease recurrence.  The BCI risk assessment  is based on data from a recently completed large, randomized, retrospective trial.(1)

"The results presented in San Antonio today become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index," said Richard Ding, chief executive officer of bioTheranostics. "We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence."

The Breast Cancer Index is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. This population represents the majority of breast cancers diagnosed each year.

Data presented today are from the MA.17 study, a previously conducted, randomized prospective trial.  This study evaluated the role of adjuvant endocrine therapy with letrozole in reducing the risk of recurrence and improving disease-free survival among women with breast cancer who completed five years of tamoxifen therapy. As part of the study, Massachusetts General Hospital researchers Paul Goss, MD, PhD and Dennis Sgroi, MD retrospectively evaluated the ability of the Breast Cancer Index to distinguish those patients at risk of late recurrence and those who
'/>"/>

SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
2. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
3. Reportlinker Adds Breast Cancer Drug Futures
4. LCS Constructors, Inc. Supports the Cure and Breast Cancer Awareness Month
5. Leading Journal Turns Up the Heat on Cutting-Edge Breast Cancer Treatment
6. K-State Research Team Investigates Mutated Genes Role in Breast Cancer
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
9. Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short ... Side” published as a tribute to his mentor ... Short Story” category of the 2014 USA Best ... of USA Book News, said this year’s contest yielded ... Simon & Schuster, Penguin, John Wiley & Sons, Houghton ...
(Date:11/21/2014)... November 20, 2014 The November 2014 ... as an open access journal featuring the following articles:, ... proteins to preserve photoresponsiveness in the retina , ... in situ hybridization using chromogenic substrates in zebrafish , ... RNA, and protein electrophoresis , Nuclear LC3-positive ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
Breaking Biology Technology:Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... (NTI (R)) (Nasdaq: NTII ) today announced the ... 31, 2007., Paul Freiman, president and chief executive ... occasion of his 75th birthday. Dr.,Cape is a legend ... board,has been outstanding. Prior to joining the board, Dr. ...
... FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire-,FirstCall/ ... and GBP IP, LLC, an,affiliate of GBP Capital, ... announced that the two companies have entered,into an ... gene,delivery technology, commonly referred to as lentiviral vectors. ...
... 20 Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) ... randomized, double-blind, placebo-controlled Phase 2a clinical,trial of MEM ... in cognitive impairment associated with schizophrenia (CIAS). The,trial ... cognitive effects,of three doses of MEM 3454 in ...
Cached Biology Technology:Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 2Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 3Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 4Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 5Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... --  News Highlights: , ... Partners Data Lake, an agile data and analytics ... allow researcher and clinicians to explore and develop ... of patients , The Partners Data Lake ... Partners system, breaking down physical barriers for collaboration ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... , Results from the first ever European-wide retrospective analysis ... both D-penicillamine and trientine continue to be effective treatments, ... free from a liver transplant. , Wilson disease is ... not excreted by the body effectively, leading to excess ...
... Researchers at The Johns Hopkins University School of ... to become contaminated with unacceptably high levels of bacteria, ... operated faucets. The study will be presented on ... Healthcare Epidemiology of America (SHEA). Electronic-eye, non-touch faucets ...
... Va.--The Department of the Navy announced today the award ... academic institutions as part of the Office of Naval ... Young Investigator Program is an important part of the ... (STEM) outreach programs," said Secretary of the Navy Ray ...
Cached Biology News:European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease 2Electronic faucets unsafe for use in high-risk patient hospital settings 2
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
Biology Products: